SCHEDULE: Foresite Capital Adjusts Alumis Stake
Beneficial Ownership Filing Amendment
Foresite Capital Fund VI LP and related entities have amended their Schedule 13D filing to reflect a disposition of Alumis Inc. common stock.
Summary
- This filing is an amendment (Amendment No. 4) to a Schedule 13D, originally filed on July 5, 2024, concerning the beneficial ownership of Alumis Inc. common stock.
- The amendment is filed by Foresite Capital Fund VI, L.P. and several related entities, including Foresite Capital Management VI, LLC, Foresite Capital Fund V, L.P., Labs Co-Invest V, LLC, Foresite Capital Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC, Foresite Labs Fund I, L.P., Foresite Labs Management I, LLC, Foresite Labs Affiliates 2021, LLC, Foresite Labs, LLC, and James B. Tananbaum.
- The primary purpose of this amendment is to report the disposition of common stock by Foresite Labs Affiliates 2021, LLC and Foresite Labs, LLC, and to update the aggregate percentage of common stock owned by James B. Tananbaum.
- As of March 12, 2026, the total number of Alumis Inc. shares outstanding was 123,139,425.
- James B. Tananbaum, through various funds and entities, beneficially owns 15,693,820 shares, representing 12.7% of the outstanding common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update to reflect stock dispositions and ownership adjustments rather than a significant strategic announcement or performance indicator.
Negatives
- Foresite Labs Affiliates 2021, LLC and Foresite Labs, LLC have disposed of their holdings in Alumis Inc. common stock.
Future Outlook
The Reporting Persons may, from time to time, acquire additional shares of Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners. Any actions will depend on factors such as price levels, market conditions, the Issuer's performance, and alternative investment opportunities.
Industry Context
StockSavvy.ai notes that this Schedule 13D amendment from Foresite Capital indicates a shift in their investment position in Alumis Inc., a biotechnology company. Such filings are crucial for tracking significant ownership changes and potential strategic moves by major investors in the life sciences sector.
Stakeholder Impact
- Shareholders may be impacted by changes in significant ownership stakes, which could influence market perception and stock price.
- The disposition of shares by Foresite Labs Affiliates and Foresite Labs may signal a change in their investment strategy or outlook for Alumis Inc.
Next Steps
- The Reporting Persons may acquire additional shares, retain existing shares, or sell shares in the open market or private transactions.
- The Reporting Persons may distribute shares to their members or limited partners.
Key Dates
| Date | Description |
|---|---|
| 2021-02-01T00:00:00.000Z | Labs Affiliates purchased 5,500,000 shares of Common Stock from the Issuer. |
| 2021-02-01T00:00:00.000Z | Fund V and Labs Co-Invest purchased an aggregate of 10,000,000 shares of Series Seed Redeemable Convertible Preferred Stock. |
| 2021-03-01T00:00:00.000Z | Fund V purchased 5,250,000 shares of Series A Redeemable Convertible Preferred Stock and Opportunity Fund V purchased 2,250,000 shares of Series A Redeemable Convertible Preferred Stock. |
| 2021-03-01T00:00:00.000Z | Issuer issued convertible promissory notes to Fund V, Opportunity Fund V and Labs Fund I with a total principal amount of $30.0 million. |
| 2021-08-01T00:00:00.000Z | Issuer issued additional convertible promissory notes to Labs Fund I with a total principal amount of $1.5 million. |
| 2021-09-01T00:00:00.000Z | Issuer amended and restated all outstanding convertible promissory notes and issued an additional convertible promissory note to Labs Fund I with a total principal amount of $6.0 million. |
| 2021-12-01T00:00:00.000Z | Convertible notes held by Fund V, Opportunity Fund V and Labs Fund I automatically converted into an aggregate 9,760,088 shares of Series B-1 Redeemable Convertible Preferred Stock. |
| 2023-05-01T00:00:00.000Z | Fund V, Opportunity Fund V, Labs Fund I, and Fund VI purchased an aggregate of 4,900,000 shares of Series B-2 Redeemable Convertible Preferred Stock at $5.00 per share. |
| 2023-10-01T00:00:00.000Z | Fund V, Opportunity Fund V, Labs Fund I, and Fund VI purchased an aggregate of 2,424,553 shares of Series B-2 Redeemable Convertible Preferred Stock at $5.00 per share. |
| 2024-03-04T00:00:00.000Z | Amended and Restated Investors' Rights Agreement entered into. |
| 2024-03-04T00:00:00.000Z | Letter agreement with underwriters entered into. |
| 2024-03-01T00:00:00.000Z | Fund V, Opportunity Fund V, Labs Fund I, and Fund VI purchased Series C Redeemable Convertible Preferred Stock at $3.13826 per share. |
| 2024-05-01T00:00:00.000Z | Fund V, Opportunity Fund V, Labs Fund I, and Fund VI purchased Series C Redeemable Convertible Preferred Stock at $3.13826 per share. |
| 2024-06-20T00:00:00.000Z | Issuer effected a 1-for-4.675 reverse stock split. |
| 2024-06-24T00:00:00.000Z | Form of Lock-Up Agreement filed as Exhibit A to the Underwriting Agreement. |
| 2024-07-01T00:00:00.000Z | Closing of the Issuer's initial public offering (IPO). |
| 2024-07-05T00:00:00.000Z | Original Schedule 13D filing date. |
| 2025-01-12T00:00:00.000Z | Amendment No. 3 to Schedule 13D filed. |
| 2025-05-02T00:00:00.000Z | Fund VI purchased 25,000 shares of Common Stock in an open market purchase. |
| 2025-05-06T00:00:00.000Z | Fund VI purchased 20,000 shares of Common Stock in an open market purchase. |
| 2025-05-07T00:00:00.000Z | Amendment No. 1 to Schedule 13D filed. |
| 2025-06-10T00:00:00.000Z | Amendment No. 2 to Schedule 13D filed. |
| 2025-11-17T00:00:00.000Z | Opportunity Fund V purchased 50,000 shares and 150,000 shares of Common Stock in open market purchases. |
| 2025-11-18T00:00:00.000Z | Opportunity Fund V purchased 117,374 shares of Common Stock in an open market purchase. |
| 2025-11-19T00:00:00.000Z | Opportunity Fund V purchased 190,500 shares of Common Stock in an open market purchase. |
| 2025-11-21T00:00:00.000Z | Opportunity Fund V purchased 72,212 shares of Common Stock in an open market purchase. |
| 2026-01-08T00:00:00.000Z | Issuer filed Prospectus Supplement detailing the Follow-on Offering. |
| 2026-01-08T00:00:00.000Z | Fund V purchased 117,647 shares and Opportunity Fund V purchased 294,117 shares of Common Stock in the Follow-on Offering. |
| 2026-01-09T00:00:00.000Z | Form of Lock-Up Agreement filed as Exhibit A to the Issuer's Form 8-K. |
| 2026-03-12T00:00:00.000Z | Date as of which Alumis, Inc. common stock outstanding was 123,139,425. |
| 2026-03-19T00:00:00.000Z | Alumis, Inc.'s Form 10-K filed with the SEC. |
| 2026-04-01T00:00:00.000Z | Labs Affiliates effected a pro rata distribution of 1,176,470 shares of Common Stock to its members. |
| 2026-04-01T00:00:00.000Z | Labs effected a pro rata distribution of 1,123,337 shares of Common Stock to its members. |
| 2026-04-03T00:00:00.000Z | Date of signature for Amendment No. 4 to Schedule 13D. |
Keywords
Alumis Inc., Schedule 13D, Foresite Capital, Beneficial Ownership, Stock Disposition, Amendment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.